Atacand to be divested to Cheplapharm in Europe
24 July 2018 07:00 BST Atacand to be divested to Cheplapharm in Europe Agreement expands the commercial potential of Atacand in 28 European countries AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine for the treatment of heart failure and hypertension. Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca, said: "This